Aligos Therapeutics (ALGS) News Today $39.84 +1.49 (+3.89%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) biggest owners are retail investors who got richer after stock soared 17% last weekDecember 21 at 6:42 PM | finance.yahoo.comCharles Schwab Investment Management Inc. Lowers Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS)Charles Schwab Investment Management Inc. cut its position in Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) by 61.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,980 shareDecember 21 at 3:08 AM | marketbeat.comHead to Head Survey: Anavex Life Sciences (NASDAQ:AVXL) & Aligos Therapeutics (NASDAQ:ALGS)December 20 at 1:27 AM | americanbankingnews.comAligos Therapeutics announces inducement grants under Nasdaq listing ruleDecember 14, 2024 | markets.businessinsider.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 13, 2024 | globenewswire.comAligos Therapeutics: Promising Pipeline With Cash And Dilution RisksDecember 11, 2024 | seekingalpha.comBaker BROS. Advisors LP Has $719,000 Position in Aligos Therapeutics, Inc. (NASDAQ:ALGS)Baker BROS. Advisors LP lessened its stake in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) by 96.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 83,055 shares of the company's stockDecember 2, 2024 | marketbeat.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short InterestAligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) was the recipient of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 291,500 shares, an increase of 140.3% from the October 31st total of 121,300 shares. Approximately 11.5% of the company's shares are short sold. Based on an average trading volume of 266,300 shares, the days-to-cover ratio is currently 1.1 days.November 28, 2024 | marketbeat.comAligos Therapeutics to Present at Investor Conferences in DecemberNovember 26, 2024 | markets.businessinsider.comAligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024November 19, 2024 | globenewswire.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Growth in Short InterestAligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) saw a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 121,300 shares, an increase of 46.5% from the October 15th total of 82,800 shares. Based on an average daily volume of 145,700 shares, the short-interest ratio is currently 0.8 days. Approximately 4.8% of the company's stock are sold short.November 14, 2024 | marketbeat.comAligos Therapeutics trading halted, volatility trading pauseNovember 12, 2024 | markets.businessinsider.comAligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial ResultsNovember 6, 2024 | globenewswire.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Drop in Short InterestAligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totalling 82,800 shares, a decrease of 31.0% from the September 30th total of 120,000 shares. Currently, 3.7% of the company's stock are sold short. Based on an average daily volume of 62,300 shares, the days-to-cover ratio is currently 1.3 days.October 27, 2024 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Shares Down 5.4% - What's Next?Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 5.4% - Here's What HappenedOctober 25, 2024 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading Volume - Should You Buy?Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading Volume - Here's What HappenedOctober 24, 2024 | marketbeat.comAligos Therapeutics’ Promising Clinical Advancements and Buy Rating Driven by Strong Market PotentialOctober 24, 2024 | markets.businessinsider.comAligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of Aligos Therapeutics in a research note on Wednesday.October 23, 2024 | marketbeat.comAligos announces FDA cleared IND for Phase 1 DDI study of ALG-000184October 23, 2024 | markets.businessinsider.comAligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184October 22, 2024 | finance.yahoo.comAligos Therapeutics (NASDAQ:ALGS) Shares Gap Up - Here's What HappenedAligos Therapeutics (NASDAQ:ALGS) Shares Gap Up - What's Next?October 15, 2024 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Trading Down 8.4% - Should You Sell?Aligos Therapeutics (NASDAQ:ALGS) Shares Down 8.4% - Here's What HappenedOctober 14, 2024 | marketbeat.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 11, 2024 | globenewswire.comAligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading Volume - Still a Buy?Aligos Therapeutics (NASDAQ:ALGS) Sees Large Volume Increase - Time to Buy?October 10, 2024 | marketbeat.comAligos Therapeutics appoints new VP of Business DevelopmentOctober 3, 2024 | uk.investing.comAligos Therapeutics (NASDAQ:ALGS) Shares Down 6.2% Aligos Therapeutics (NASDAQ:ALGS) Shares Down 6.2%October 3, 2024 | marketbeat.comAligos Therapeutics Appoints David Perry as Vice President of Business DevelopmentOctober 1, 2024 | globenewswire.comAligos Therapeutics to Present at Investor Conferences in OctoberSeptember 30, 2024 | globenewswire.comPiper Sandler Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)September 25, 2024 | markets.businessinsider.comAligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical OfficerSeptember 24, 2024 | markets.businessinsider.comAligos Therapeutics (NASDAQ:ALGS) Sees Large Volume IncreaseAligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading VolumeSeptember 24, 2024 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Reaches New 52-Week Low at $8.28Aligos Therapeutics (NASDAQ:ALGS) Hits New 12-Month Low at $8.28September 23, 2024 | marketbeat.comBuy Recommendation: Aligos Therapeutics’ ALG-055009 Shows Promise in Phase 2a with Advancement and Partnership PotentialSeptember 21, 2024 | markets.businessinsider.comAligos Therapeutics (NASDAQ:ALGS) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a research report on Friday.September 20, 2024 | marketbeat.comAligos' fatty liver disease treatment meets main goal in mid-stage studySeptember 20, 2024 | reuters.comAligos posts initial mid-stage trial results for MASH candidateSeptember 20, 2024 | msn.comAligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASHSeptember 19, 2024 | globenewswire.comAligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024September 18, 2024 | globenewswire.comInvenra Welcomes Three Industry Leaders to Its Board of DirectorsSeptember 17, 2024 | businesswire.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 18.3% in AugustAligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 14,900 shares, a growth of 18.3% from the August 15th total of 12,600 shares. Based on an average trading volume of 34,700 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.7% of the company's shares are short sold.September 15, 2024 | marketbeat.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 13, 2024 | globenewswire.comAligos Therapeutics (NASDAQ:ALGS) Stock Price Up 12.3%Aligos Therapeutics (NASDAQ:ALGS) Trading 12.3% HigherSeptember 12, 2024 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $13.79Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $13.79September 11, 2024 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Sees Strong Trading VolumeAligos Therapeutics (NASDAQ:ALGS) Sees Large Volume IncreaseSeptember 10, 2024 | marketbeat.comAligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $11.94Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $11.94September 6, 2024 | marketbeat.comAligos Therapeutics, Inc. (5WK0.F)August 30, 2024 | ca.finance.yahoo.comAligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $13.16Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $13.16August 30, 2024 | marketbeat.comShort Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Decreases By 95.5%Aligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) was the target of a large decrease in short interest in the month of August. As of August 15th, there was short interest totalling 12,600 shares, a decrease of 95.5% from the July 31st total of 281,100 shares. Based on an average daily trading volume, of 19,900 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.6% of the shares of the stock are short sold.August 27, 2024 | marketbeat.comAligos Therapeutics Share Price (ALGS.US)August 24, 2024 | lse.co.ukAligos Therapeutics, Inc. Expected to Post Q3 2024 Earnings of ($4.40) Per Share (NASDAQ:ALGS)Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) - Equities researchers at HC Wainwright issued their Q3 2024 earnings estimates for Aligos Therapeutics in a research report issued on Tuesday, August 20th. HC Wainwright analyst E. Arce expects that the company will earn ($4.40) per share forAugust 22, 2024 | marketbeat.com Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now ALGS Media Mentions By Week ALGS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALGS News Sentiment▼0.570.60▲Average Medical News Sentiment ALGS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALGS Articles This Week▼22▲ALGS Articles Average Week Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cartesian Therapeutics News Today Monte Rosa Therapeutics News Today Esperion Therapeutics News Today Alpha Teknova News Today ChromaDex News Today Organogenesis News Today Zevra Therapeutics News Today Verve Therapeutics News Today Corvus Pharmaceuticals News Today SIGA Technologies News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALGS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
